Friday, July 10, 2026

pharma · Alopecia areata · Multiple myeloma

First Biotech (Australia)

Pfizer Australia Pty is a pharma organization headquartered in AU. Primary therapeutic focus areas include Alopecia areata, Multiple myeloma, Heart failure, Acute Migraine (with or without aura), Transthyretin amyloidosi

Norwest House, 710 Collins Street, Melbourne, VIC 3008, AU HQ
2017 Founded
2 Employees
TGA registrant Type
Company details
Status
Public
HQ
Norwest House, 710 Collins Street, Melbourne, VIC 3008, AU
Founded
2017
Employees
2
Programs
126
Drugs
208
Patents
0
Clinical program

A6281331

Phase 1 · other · Growth hormone deficiency

A6281331 for Growth hormone deficiency is a Phase 1 program (other) at Pfizer Australia Pty Ltd with 1 ClinicalTrials.gov record(s).

Internal code A6281331

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Pfizer Australia Pty Ltd
Phase
Phase 1
Modality
other
Indication
Growth hormone deficiency
Status
active
Trials
1